Debiopharm International SA

Debiopharm International SA

Debiopharm International SA

Overview
Date Founded

1979

Headquarters

5-7, chemin Messidor,Lausanne, Vaud 1002

Type of Company

Private

Industries

Pharmaceuticals

Company Description

Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland.

Executives & Employees

Chief Executive Officer

General Counsel

Director, Head of Search & Evaluation & Scientific Innovation

Director, Project Management Office

Director, Business Development, Licensing, Marketing & Communication

Director, Regulatory Affairs, Business Intelligence & Market Access

Director, Quality Management & Documentation

Director, Human Resources

Director-Finance & Administration

Senior Vice President, Portfolio & Project Management

Paths to Debiopharm International SA
Potential Connections via
Relationship Science
You
Debiopharm International SA
Recent Transactions
Details Hidden

Meridian Bioscience, Inc. purchases GenePOC, Inc. from Debiopharm International SA

Details Hidden

Debiopharm International SA purchases Affinium Pharmaceuticals Ltd. from SV Health Investors LLP, Genesys Capital Partners, Inc., Forward Ventures Services LLC, Ontario Capital Growth Corp.

Transaction Advisors
Legal Advisor

Advised onDebiopharm International SA purchases Affinium Pharmaceuticals Ltd. from SV Health Investors LLP, Genesys Capital Partners, Inc., Forward Ventures Services LLC, Ontario Capital Growth Corp.

Legal Advisor

Advised onGecina purchases Eurosic SAS

Legal Advisor

Advised onDebiopharm International SA purchases Affinium Pharmaceuticals Ltd. from SV Health Investors LLP, Genesys Capital Partners, Inc., Forward Ventures Services LLC, Ontario Capital Growth Corp.

Legal Advisor

Advised onDebiopharm International SA purchases Affinium Pharmaceuticals Ltd. from SV Health Investors LLP, Genesys Capital Partners, Inc., Forward Ventures Services LLC, Ontario Capital Growth Corp.

Attorney

Advised onDebiopharm International SA purchases Affinium Pharmaceuticals Ltd. from SV Health Investors LLP, Genesys Capital Partners, Inc., Forward Ventures Services LLC, Ontario Capital Growth Corp.

Investments
Details Hidden

GenePOC, Inc. develops rapid molecular devices to detect genes at point-of-care. Its product includes an integrated portable instrument for the prevention and early detection of infectious diseases based on a centripetal technology platform. Its product also includes GenePOC disposable, a device for performing nucleic acid-based diagnostics at POC. The company's products are also used for infectious disease, rapid food microbiology, and human pharmacogenetic testing applications. The company was founded by Michel G. Bergeron in 2007 and is headquartered in Quebec, Canada.

Details Hidden

Diagnoplex SA develops molecular diagnostics for colon cancer. It lead product, Colox is a minimally-invasive blood test developed for the systematic screening and detection of early and advanced colorectal cancer. The company was founded in April 2005 by Stavros Therianos, Curzio Roberto Maria Rüegg, Jacques R. Essinger and Jean-Pierre Rosat and is headquartered in Lausanne, Switzerland.

Details Hidden

Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands.

Suppliers
Immunogen Inc. Medical Support Services | WALTHAM, MA

ImmunoGen, Inc. is a biotechnology company, which engages in discovering and developing antibody-drug conjugate therapies that meaningfully improve the lives of people with cancer. Its product candidates include Mirvetuximab soravtansine, Coltuximab ravtansine, IMGN7779 and IMGN632. The company was founded in March 1981 and is headquartered in Waltham, MA.

Veeva Systems, Inc. Other Business & Consulting Services | PLEASANTON, CA

Veeva Systems, Inc. engages in the provision of industry-specific, cloud-based software solutions for the life sciences industry. Its solutions enable pharmaceutical and other life sciences companies to realize the benefits of modern cloud-based architectures and mobile applications for their most critical business functions, without compromising industry-specific functionality or regulatory compliance. The firm's customer relationship management solutions enable its customers to increase the productivity and compliance of their sales and marketing functions. Its regulated content management and collaboration solutions enable its customers to more efficiently manage a regulated, content-centric processes across the enterprise. The company's customer master solution enables customers to more effectively manage complex healthcare provider and healthcare organization data. The company was founded by Mark Armenante, Peter P. Gassner, Doug Ostler, Mitch Wallace and Matthew J. Wallach on January 12, 2007 and is headquartered in Pleasanton, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Debiopharm International SA. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Debiopharm International SA's profile does not indicate a business or promotional relationship of any kind between RelSci and Debiopharm International SA.